{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:27:37Z","timestamp":1790882857941,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T00:00:00Z","timestamp":1616803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Amgen Europe GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00198-021-05927-1","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T01:02:34Z","timestamp":1616806954000},"page":"2011-2021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost effectiveness of romosozumab versus teriparatide for severe postmenopausal osteoporosis in Japan"],"prefix":"10.1007","volume":"32","author":[{"given":"H.","family":"Hagino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"McClung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. R.","family":"Gandra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Charokopou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-0920","authenticated-orcid":false,"given":"B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Stollenwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,27]]},"reference":[{"issue":"1","key":"5927_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.5152\/eurjrheum.2016.048","volume":"4","author":"T S\u00f6zen","year":"2017","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N\u00c7 (2017) An overview and management of osteoporosis. Eur J Rheumatol 4(1):46","journal-title":"Eur J Rheumatol"},{"issue":"6","key":"5927_CR2","first-page":"797","volume":"22","author":"M Iki","year":"2012","unstructured":"Iki M (2012) Epidemiology of osteoporosis in Japan. Clin Calcium 22(6):797\u2013803","journal-title":"Clin Calcium"},{"issue":"12","key":"5927_CR3","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00198-005-1974-5","volume":"16","author":"H Hagino","year":"2005","unstructured":"Hagino H, Katagiri H, Okano T, Yamamoto K, Teshima R (2005) Increasing incidence of hip fracture in Tottori Prefecture, Japan: Trend from 1986 to 2001. Osteoporos Int 16(12):1963\u20131968","journal-title":"Osteoporos Int"},{"key":"5927_CR4","first-page":"286","volume":"46","author":"K Moriwaki","year":"2009","unstructured":"Moriwaki K, Kamae I (2009) Socioeconomic aspect of osteoporosis: burden of illness research for osteoporosis. J Jpn J Geriatr 46:286\u2013298","journal-title":"J Jpn J Geriatr"},{"issue":"15","key":"5927_CR5","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377(15):1417\u20131427","journal-title":"N Engl J Med"},{"issue":"10117","key":"5927_CR6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler DL, Marin F, Zerbini CA, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391(10117):230\u2013240","journal-title":"Lancet"},{"issue":"2","key":"5927_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/jbm4.10041","volume":"2","author":"BZ Leder","year":"2018","unstructured":"Leder BZ (2018) Optimizing sequential and combined anabolic and antiresorptive osteoporosis therapy. JBMR plus 2(2):62\u201368","journal-title":"JBMR plus"},{"key":"5927_CR8","unstructured":"Committee of Japanese Guidelines for the Prevention and Treatment of Osteoporosis (2015) Japanese guidelines for the prevention and treatment of osteoporosis (2015 edition). Life Science Publishing, Tokyo, Japan (in Japanese)"},{"issue":"4","key":"5927_CR9","first-page":"499","volume":"2","author":"D Bodenner","year":"2007","unstructured":"Bodenner D, Redman C, Riggs A (2007) Teriparatide in the management of osteoporosis. Clin Interv Aging 2(4):499","journal-title":"Clin Interv Aging"},{"issue":"10102","key":"5927_CR10","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB, Bolognese MA, Brown JP, Daizadeh NS, Dokoupilova E, Engelke K, Finkelstein JS, Genant HK (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390(10102):1585\u20131594","journal-title":"Lancet"},{"issue":"3","key":"5927_CR11","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00198-010-1424-x","volume":"22","author":"B J\u00f6nsson","year":"2011","unstructured":"J\u00f6nsson B, Str\u00f6m O, Eisman JA, Papaioannou A, Siris E, Tosteson A, Kanis JA (2011) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967\u2013982","journal-title":"Osteoporos Int"},{"issue":"5","key":"5927_CR12","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40258-013-0047-8","volume":"11","author":"A Parthan","year":"2013","unstructured":"Parthan A, Kruse M, Yurgin N, Huang J, Viswanathan HN, Taylor D (2013) Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US. Appl Health Econ Health Policy 11(5):485\u2013497","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"5927_CR13","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s00198-017-3973-8","volume":"28","author":"K Moriwaki","year":"2017","unstructured":"Moriwaki K, Mouri M, Hagino H (2017) Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan. Osteoporos Int 28(6):1939\u20131950","journal-title":"Osteoporos Int"},{"issue":"4","key":"5927_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","volume":"34","author":"ML Bouxsein","year":"2019","unstructured":"Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, Marin F, Cauley JA, Bauer DC, Black DM (2019) Change in bone density and reduction in fracture risk: a meta-regression of published trials. J Bone Miner Res 34(4):632\u2013642","journal-title":"J Bone Miner Res"},{"key":"5927_CR15","unstructured":"Ministry of Health, L.a.W. The 4th NDB Open Data (in Japanese). [cited 2020 November 13th]; Available from: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000177221_00003.html."},{"issue":"3","key":"5927_CR16","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jval.2016.08.726","volume":"20","author":"T Shiroiwa","year":"2017","unstructured":"Shiroiwa T, Fukuda T, Ikeda S, Takura T, Moriwaki K (2017) Development of an official guideline for the economic evaluation of drugs\/medical devices in Japan. Value Health 20(3):372\u2013378","journal-title":"Value Health"},{"issue":"7","key":"5927_CR17","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.clinthera.2017.05.348","volume":"39","author":"CE O\u2019Hanlon","year":"2017","unstructured":"O\u2019Hanlon CE, Parthan A, Kruse M, Cartier S, Stollenwerk B, Jiang Y, Caloyeras JP, Crittenden DB, Barron R (2017) A model for assessing the clinical and economic benefits of bone-forming agents for reducing fractures in postmenopausal women at high, near-term risk of osteoporotic fracture. Clin Ther 39(7):1276\u20131290","journal-title":"Clin Ther"},{"issue":"9","key":"5927_CR18","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00198-019-05064-w","volume":"30","author":"A Svedbom","year":"2019","unstructured":"Svedbom A, Hadji P, Hernlund E, Thoren R, McCloskey E, Stad R, Stollenwerk B (2019) Cost-effectiveness of pharmacological fracture prevention for osteoporosis as prescribed in clinical practice in France, Germany, Italy, Spain, and the United Kingdom. Osteoporos Int 30(9):1745\u20131754","journal-title":"Osteoporos Int"},{"key":"5927_CR19","unstructured":"World Health Organization (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: report of a WHO study group [meeting held in Rome from 22 to 25 June 1992]. World Health Organization"},{"issue":"1","key":"5927_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11657-018-0456-2","volume":"13","author":"Y Taguchi","year":"2018","unstructured":"Taguchi Y, Inoue Y, Kido T, Arai N (2018) Treatment costs and cost drivers among osteoporotic fracture patients in Japan: a retrospective database analysis. Arch Osteoporos 13(1):45","journal-title":"Arch Osteoporos"},{"issue":"5","key":"5927_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1359\/jbmr.1999.14.5.821","volume":"14","author":"DM Black","year":"1999","unstructured":"Black DM, Arden NK, Palermo L, Pearson J, Cummings SR, S.o.O.F.R. Group (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res 14(5):821\u2013828","journal-title":"J Bone Miner Res"},{"key":"5927_CR22","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert (Forteo) (in Japanese). [cited 2020 September 9th]; Available from: https:\/\/www.info.pmda.go.jp\/go\/pdf\/530471_2439400G1020_1_16."},{"issue":"11","key":"5927_CR23","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1080\/03007995.2017.1354826","volume":"33","author":"S Soen","year":"2017","unstructured":"Soen S, Fujiwara S, Takayanagi R, Kajimoto K, Tsujimoto M, Kimura S, Sato M, Krege JH, Enomoto H (2017) Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS). Cure med Res Opin 33(11):2049\u20132056","journal-title":"Cure med Res Opin"},{"issue":"10","key":"5927_CR24","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00198-007-0406-0","volume":"18","author":"H Ideguchi","year":"2007","unstructured":"Ideguchi H, Ohno S, Hattori H, Ishigatsubo Y (2007) Persistence with bisphosphonate therapy including treatment courses with multiple sequential bisphosphonates in the real world. Osteoporos Int 18(10):1421\u20131427","journal-title":"Osteoporos Int"},{"issue":"24","key":"5927_CR25","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L (2006) Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296(24):2927\u20132938","journal-title":"JAMA"},{"issue":"2","key":"5927_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00198-018-4798-9","volume":"30","author":"K Moriwaki","year":"2019","unstructured":"Moriwaki K, Fukuda H (2019) Cost-effectiveness of implementing guidelines for the treatment of glucocorticoid-induced osteoporosis in Japan. Osteoporos Int 30(2):299\u2013310","journal-title":"Osteoporos Int"},{"issue":"8","key":"5927_CR27","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1359\/jbmr.2003.18.8.1547","volume":"18","author":"S Fujiwara","year":"2003","unstructured":"Fujiwara S, Kasagi F, Masunari N, Naito K, Suzuki G, Fukunaga M (2003) Fracture prediction from bone mineral density in Japanese men and women. J Bone Miner Res 18(8):1547\u20131553","journal-title":"J Bone Miner Res"},{"issue":"7041","key":"5927_CR28","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1136\/bmj.312.7041.1254","volume":"312","author":"D Marshall","year":"1996","unstructured":"Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312(7041):1254\u20131259","journal-title":"BMJ"},{"issue":"4","key":"5927_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1359\/jbmr.2000.15.4.721","volume":"15","author":"CM Klotzbuecher","year":"2000","unstructured":"Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721\u2013739","journal-title":"J Bone Miner Res"},{"issue":"4","key":"5927_CR30","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1302\/0301-620X.89B4.18552","volume":"89","author":"M Tsuboi","year":"2007","unstructured":"Tsuboi M, Hasegawa Y, Suzuki S, Wingstrand H, Thorngren K-G (2007) Mortality and mobility after hip fracture in Japan: a ten-year follow-up. J Bone Joint Surg Br Vol 89(4):461\u2013466","journal-title":"J Bone Joint Surg Br Vol"},{"issue":"6","key":"5927_CR31","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1093\/ije\/24.6.1171","volume":"24","author":"PD Ross","year":"1995","unstructured":"Ross PD, Fujiwara S, Huang C, Davis JW, Epstein RS, Wasnich RD, Kodama K, Melton LJ III (1995) Vertebral fracture prevalence in women in Hiroshima compared to Caucasians or Japanese in the US. Int J Epidemiol 24(6):1171\u20131177","journal-title":"Int J Epidemiol"},{"issue":"1","key":"5927_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00198-012-2068-9","volume":"24","author":"N Freemantle","year":"2013","unstructured":"Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C (2013) Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 24(1):209\u2013217","journal-title":"Osteoporos Int"},{"issue":"5","key":"5927_CR33","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster J-Y, Zanchetta JR, Wasserman SM (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370(5):412\u2013420","journal-title":"N Engl J Med"},{"key":"5927_CR34","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3389\/fphar.2017.00803","volume":"8","author":"V Pavone","year":"2017","unstructured":"Pavone V, Testa G, Giardina S, Vescio A, Restivo DA, Sessa G (2017) Pharmacological therapy of osteoporosis: a systematic current review of literature. Front Pharmacol 8:803","journal-title":"Front Pharmacol"},{"issue":"16","key":"5927_CR35","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543","journal-title":"N Engl J Med"},{"key":"5927_CR36","unstructured":"Japan Ministry of Health, L., and Welfare,. Medical fee schedule (in Japanese). [cited 2020 September 10th]; Available from: https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000188411_00027.html."},{"key":"5927_CR37","unstructured":"Medical Fee Schedule, Igaku-tsushin-sha, Tokyo, Japan (in Japanese). 2020"},{"issue":"1","key":"5927_CR38","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11657-018-0448-2","volume":"13","author":"T Mori","year":"2018","unstructured":"Mori T, Tamiya N, Jin X, Jeon B, Yoshie S, Iijima K, Ishizaki T (2018) Estimated expenditures for hip fractures using merged healthcare insurance data for individuals aged\u2265 75 years and long-term care insurance claims data in Japan. Arch Osteoporos 13(1):37","journal-title":"Arch Osteoporos"},{"issue":"2","key":"5927_CR39","first-page":"75","volume":"10","author":"S Nawata","year":"2000","unstructured":"Nawata S (2000) and Society, EuroQol study of the elderly general population: relationship with IADL and other attributes. J. Health Care 10(2):75\u201386","journal-title":"Health Care"},{"issue":"4","key":"5927_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00198-008-0685-0","volume":"20","author":"H Hagino","year":"2009","unstructured":"Hagino H, Furukawa K, Fujiwara S, Okano T, Katagiri H, Yamamoto K, Teshima R (2009) Recent trends in the incidence and lifetime risk of hip fracture in Tottori, Japan. Osteoporos Int 20(4):543\u2013548","journal-title":"Osteoporos Int"},{"issue":"5","key":"5927_CR41","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00198-008-0761-5","volume":"20","author":"H Hagino","year":"2009","unstructured":"Hagino H, Nakamura T, Fujiwara S, Oeki M, Okano T, Teshima R (2009) Sequential change in quality of life for patients with incident clinical fractures: a prospective study. Osteoporos Int 20(5):695\u2013702","journal-title":"Osteoporos Int"},{"issue":"5","key":"5927_CR42","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie S-AM, Zhu Y, Foley K, Lee H, Neer RM (2014) Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab 99(5):1694\u20131700","journal-title":"J Clin Endocrinol Metab"},{"key":"5927_CR43","unstructured":"Pharmaceuticals and Medical Devices Agency. Package insert (Evenity) (in Japanese). [cited 2020 September 11th]; Available from: https:\/\/www.info.pmda.go.jp\/go\/pdf\/112922_3999449G1025_1_05."},{"issue":"2","key":"5927_CR44","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.clinthera.2006.01.002","volume":"28","author":"FJ Penning-van Beest","year":"2006","unstructured":"Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM (2006) Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 28(2):236\u2013242","journal-title":"Clin Ther"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05927-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-05927-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05927-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T03:54:39Z","timestamp":1634097279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-05927-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,27]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["5927"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-05927-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,27]]},"assertion":[{"value":"4 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HH has received grant\/research support from Asahi Kasei Pharma, Astellas, Chugai, Eisai, Mitsubishi Tanabe Pharma, Pfizer Japan, Taisho and Teijin Pharma, has provided consultancy services to Asahi Kasei Pharma, and has received speaking fees from Amgen, Asahi Kasei Pharma, Astellas, Chugai, Eisai, Eli Lilly Japan, Mitsubishi Tanabe Pharma, Mochida, MSD, Pfizer Japan, Taisho, Teijin Pharma, and UCB Japan. SS has received grant\/research support from Amgen and Radius, has provided consultancy services to Amgen, Radius, Lilly, and Pfizer, and has received speakers\u2019 bureau from Amgen and Radius. MM has provided consultancy services to Amgen and Myovant and has received speakers\u2019 bureau from Amgen. SRG, KA, BJ, and BS are employees of Amgen and own Amgen stock. MC is an employee of UCB BioPharma. KT has no conflicts of interest to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}